Kazia Therapeutics Ret. on equity
What is the Ret. on equity of Kazia Therapeutics?
The Ret. on equity of Kazia Therapeutics Limited is -87.27%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on ASX compared to Kazia Therapeutics
What does Kazia Therapeutics do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Companies with ret. on equity similar to Kazia Therapeutics
- Unum Therapeutics has Ret. on equity of -87.78%
- Euro Manganese has Ret. on equity of -87.60%
- Velocity Property has Ret. on equity of -87.57%
- EQ has Ret. on equity of -87.47%
- DynaCERT has Ret. on equity of -87.37%
- Golden Wheel Tiandi has Ret. on equity of -87.37%
- Kazia Therapeutics has Ret. on equity of -87.27%
- China Properties has Ret. on equity of -87.22%
- Canna 8 Investment Trust has Ret. on equity of -87.11%
- Strongbridge Biopharma plc has Ret. on equity of -87.06%
- Nio Inc Nio American Depositary has Ret. on equity of -87.02%
- Copper Lake Resources has Ret. on equity of -86.95%
- Elegance Optical International has Ret. on equity of -86.91%